These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 12740257

  • 1. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.
    Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG.
    Chest; 2003 May; 123(5):1425-34. PubMed ID: 12740257
    [Abstract] [Full Text] [Related]

  • 2. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
    Campos MA, Lascano J.
    Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG, RAPID Trial Study Group.
    Lancet; 2015 Jul 25; 386(9991):360-8. PubMed ID: 26026936
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.
    Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C.
    Int J Chron Obstruct Pulmon Dis; 2020 Jul 25; 15():3193-3199. PubMed ID: 33299307
    [Abstract] [Full Text] [Related]

  • 7. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
    Sclar DA, Evans MA, Robison LM, Skaer TL.
    Clin Drug Investig; 2012 May 01; 32(5):353-60. PubMed ID: 22480280
    [Abstract] [Full Text] [Related]

  • 8. Patterns and characterization of COPD exacerbations using real-time data collection.
    Ejiofor SI, Stolk J, Fernandez P, Stockley RA.
    Int J Chron Obstruct Pulmon Dis; 2017 May 01; 12():427-434. PubMed ID: 28182151
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
    Wencker M, Banik N, Buhl R, Seidel R, Konietzko N.
    Eur Respir J; 1998 Feb 01; 11(2):428-33. PubMed ID: 9551749
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
    Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P, American College of Physicians, American College of Chest Physicians, American Thoracic Society, European Respiratory Society.
    Ann Intern Med; 2011 Aug 02; 155(3):179-91. PubMed ID: 21810710
    [Abstract] [Full Text] [Related]

  • 11. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
    Campos MA, Runken MC, Davis AM, Johnson MP, Stone GA, Buikema AR.
    Adv Ther; 2018 Apr 02; 35(4):467-481. PubMed ID: 29616482
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
    Wencker M, Fuhrmann B, Banik N, Konietzko N, Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen.
    Chest; 2001 Mar 02; 119(3):737-44. PubMed ID: 11243951
    [Abstract] [Full Text] [Related]

  • 15. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.
    Vijayasaratha K, Stockley RA.
    Int J Chron Obstruct Pulmon Dis; 2012 Mar 02; 7():789-96. PubMed ID: 23226015
    [Abstract] [Full Text] [Related]

  • 16. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
    Am J Respir Crit Care Med; 1998 Jul 02; 158(1):49-59. PubMed ID: 9655706
    [Abstract] [Full Text] [Related]

  • 17. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.
    Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK.
    Thorax; 2007 Sep 02; 62(9):806-13. PubMed ID: 17389752
    [Abstract] [Full Text] [Related]

  • 18. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
    Kueppers F.
    Curr Med Res Opin; 2011 Mar 02; 27(3):579-88. PubMed ID: 21226542
    [Abstract] [Full Text] [Related]

  • 19. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.
    Abboud RT, Ford GT, Chapman KR, Stnadards Committee of the Canadian Thoracic Society.
    Can Respir J; 2001 Mar 02; 8(2):81-8. PubMed ID: 11320399
    [Abstract] [Full Text] [Related]

  • 20. Augmentation therapy for alpha-1 antitrypsin deficiency--not enough evidence to support its use yet!
    McCarthy C, Dimitrov BD.
    COPD; 2010 Jun 02; 7(3):234; author reply 235-6. PubMed ID: 20486824
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.